| The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells M Kurachi, RA Barnitz, N Yosef, PM Odorizzi, MA DiIorio, ME Lemieux, ... Nature immunology 15 (4), 373-383, 2014 | 344 | 2014 |
| Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA SS Chandran, J Ma, MG Klatt, F Dündar, C Bandlamudi, P Razavi, ... Nature medicine 28 (5), 946-957, 2022 | 63 | 2022 |
| ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome CY Oh, MG Klatt, C Bourne, T Dao, MM Dacek, EJ Brea, SS Mun, ... Cancer immunology research 7 (12), 1984-1997, 2019 | 41 | 2019 |
| Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform RS Gejman, HF Jones, MG Klatt, AY Chang, CY Oh, SS Chandran, ... Cancer immunology research 8 (5), 672-684, 2020 | 30 | 2020 |
| Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody T Dao, SS Mun, AC Scott, CA Jarvis, T Korontsvit, Z Yang, L Liu, MG Klatt, ... Oncoimmunology 8 (7), e1570778, 2019 | 26 | 2019 |
| Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design MG Klatt, DJ Kowalewski, H Schuster, M Di Marco, J Hennenlotter, ... Oncoimmunology 5 (8), e1204504, 2016 | 23 | 2016 |
| Empirical and rational design of T cell receptor-based immunotherapies HF Jones, Z Molvi, MG Klatt, T Dao, DA Scheinberg Frontiers in Immunology 11, 585385, 2021 | 22 | 2021 |
| Solving an MHC allele–specific bias in the reported immunopeptidome MG Klatt, KN Mack, Y Bai, ZEH Aretz, LI Nathan, SS Mun, T Dao, ... JCI insight 5 (19), 2020 | 20 | 2020 |
| Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy A Charles, CM Bourne, T Korontsvit, ZEH Aretz, SS Mun, T Dao, MG Klatt, ... Oncoimmunology 10 (1), 1916243, 2021 | 17 | 2021 |
| A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies MG Klatt, T Dao, Z Yang, J Liu, SS Mun, MM Dacek, H Luo, TJ Gardner, ... Blood, The Journal of the American Society of Hematology 140 (8), 861-874, 2022 | 10 | 2022 |
| Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy AN Hasan, E Doubrovina, R Sottile, S Prockop, MG Klatt, G Heller, ... Blood Advances 6 (16), 4859-4872, 2022 | 10 | 2022 |
| A TCR mimic monoclonal antibody reactive with the “public” phospho-neoantigen pIRS2/HLA-A* 02: 01 complex T Dao, SS Mun, Z Molvi, T Korontsvit, MG Klatt, AG Khan, EK Nyakatura, ... JCI insight 7 (5), 2022 | 10 | 2022 |
| Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment CM Bourne, SS Mun, T Dao, ZEH Aretz, Z Molvi, RS Gejman, A Daman, ... Blood Advances 6 (14), 4107-4121, 2022 | 8 | 2022 |
| Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer T Dao, MG Klatt, T Korontsvit, SS Mun, S Guzman, M Mattar, O Zivanovic, ... Cancer Immunology, Immunotherapy 70, 1189-1202, 2021 | 6 | 2021 |
| Abstract CN01-03: T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers S Chandran, J Ma, MG Klatt, F Dündar, P Zumbo, MR Femia, D Betel, ... Molecular Cancer Therapeutics 18 (12_Supplement), CN01-03-CN01-03, 2019 | 5 | 2019 |
| Immunogenicity of a public neoantigen derived from mutated PIK3CA SS Chandran, J Ma, MG Klatt, F Dundar, C Bandlamudi, P Razavi, ... bioRxiv, 2021.04. 08.439061, 2021 | 4 | 2021 |
| Epigenetic drug treatment induces presentation of new class of non-exonic, cryptic neoantigens in acute myeloid leukemia cells MG Klatt, SS Mun, ND Socci, T Korontsvit, T Dao, DA Scheinberg Blood 132, 2717, 2018 | 4 | 2018 |
| A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A* 02: 01 complex T Dao, S Mun, T Korontsvit, AG Khan, MA Pohl, T White, MG Klatt, ... Plos one 17 (3), e0265534, 2022 | 3 | 2022 |
| An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments MG Klatt, ZEH Aretz, M Curcio, RS Gejman, HF Jones, DA Scheinberg Journal of proteomics 228, 103921, 2020 | 3 | 2020 |
| T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers S Chandran, J Ma, MG Klatt, F Dundar, P Zumbo, MR Femia, D Betel, ... Molecular Cancer Therapeutics 18 (12), 2019 | 2 | 2019 |
